These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23569076)

  • 1. Establishing acceptable limits of residual DNA.
    Yang H
    PDA J Pharm Sci Technol; 2013; 67(2):155-63. PubMed ID: 23569076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian Approach to Residual Host Cell DNA Safety Assessment.
    Yang H; Zhang J
    PDA J Pharm Sci Technol; 2016; 70(2):157-62. PubMed ID: 26797975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A probabilistic model for risk assessment of residual host cell DNA in biological products.
    Yang H; Zhang L; Galinski M
    Vaccine; 2010 Apr; 28(19):3308-11. PubMed ID: 20226252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety issues relating to the use of mammalian cells as hosts.
    Petricciani JC
    Dev Biol Stand; 1985; 59():149-53. PubMed ID: 3891461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of tumor induction in vivo by residual cellular DNA: quantitative considerations.
    Löwer J
    J Med Virol; 1990 May; 31(1):50-3. PubMed ID: 2198328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment on the carcinogenic potential of hybridoma cell DNA: implications for residual contaminating cellular DNA in biological products.
    Dortant PM; Claassen IJ; van Kreyl CF; van Steenis G; Wester PW
    Biologicals; 1997 Dec; 25(4):381-90. PubMed ID: 9467034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of final container residual moisture in freeze-dried biological products.
    May JC; Wheeler RM; Etz N; Del Grosso A
    Dev Biol Stand; 1992; 74():153-64. PubMed ID: 1592165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine.
    Tatalick LM; Gerard CJ; Takeya R; Price DN; Thorne BA; Wyatt LM; Anklesaria P
    Vaccine; 2005 Apr; 23(20):2628-38. PubMed ID: 15780446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Policy and health implications of using the U.S. Food and Drug Administration product design approach in reducing tobacco product risk.
    Givel M
    Curr Drug Abuse Rev; 2008 Jun; 1(2):135-41. PubMed ID: 19630712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Container Closure Integrity Testing-Method Development for Freeze-Dried Products Using Laser-Based Headspace Oxygen Analysis.
    Hede JO; Fosbøl PL; Berg SW; Dahl S
    PDA J Pharm Sci Technol; 2019; 73(2):170-180. PubMed ID: 30361284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vapor Phase Hydrogen Peroxide Decontamination or Sanitization of an Isolator for Aseptic Filling of Monoclonal Antibody Drug Product-Hydrogen Peroxide Uptake and Impact on Protein Quality.
    Hubbard A; Roedl T; Hui A; Knueppel S; Eppler K; Lehnert S; Maa YF
    PDA J Pharm Sci Technol; 2018; 72(4):348-366. PubMed ID: 29545321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016.
    Santos AMC; Doria MS; Meirinhos-Soares L; Almeida AJ; Menezes JC
    PDA J Pharm Sci Technol; 2018; 72(1):62-72. PubMed ID: 29242394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Communicating Immunogenicity-Associated Risk in Current U.S. FDA Prescription Drug Labeling: A Systematic Evaluation.
    Guinn D; Madabushi R; Wang YM; Brodsky E; Zineh I; Maxfield K
    Ther Innov Regul Sci; 2020 Nov; 54(6):1363-1371. PubMed ID: 33258100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Food and Drug Administration's perspective on plasma safety.
    Hoots WK; Abrams C; Tankersley D
    Transfus Med Rev; 2001 Apr; 15(2 Suppl 1):20-6. PubMed ID: 11441417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 3: Porcine islet product manufacturing and release testing criteria.
    Rayat GR; Gazda LS; Hawthorne WJ; Hering BJ; Hosking P; Matsumoto S; Rajotte RV
    Xenotransplantation; 2016; 23(1):38-45. PubMed ID: 26923763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equivalence of complex drug products: advances in and challenges for current regulatory frameworks.
    Hussaarts L; Mühlebach S; Shah VP; McNeil S; Borchard G; Flühmann B; Weinstein V; Neervannan S; Griffiths E; Jiang W; Wolff-Holz E; Crommelin DJA; de Vlieger JSB
    Ann N Y Acad Sci; 2017 Nov; 1407(1):39-49. PubMed ID: 28445611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. U.S. Food and Drug Administration perspective of the inclusion of effects of low-level exposures in safety and risk assessment.
    Gaylor DW; Bolger PM; Schwetz BA
    Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):391-4. PubMed ID: 9539036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.